SCHEMBL20111276

SCHEMBL20111276

CCOc1ccc2c(c1F)-c1c-2cc(C#Cc2ccc(-c3ccccc3)c(F)c2F)c(F)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 2/20 0.35
FGFR1 P11362 1/20 0.35
KDM4E B2RXH2 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
PTPRC P08575 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
MAPT P10636 4/20 0.33
EGFR P00533 1/20 0.33
ALDH1A1 P00352 4/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
ALOX5 P09917 1/20 0.32
FAAH O00519 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20111542 0.85 ADORA3 (0.39) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL20102550 0.85 RARB (0.38) FGFR2FGFR1KDM4ERAB9AHSD17B10
SCHEMBL20097219 0.79 FGFR2 (0.43) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL15256185 0.79 L3MBTL1 (0.43) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL21609908 0.78 ADORA1 (0.44) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL21609904 0.76 FGFR2 (0.44) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL20111597 0.75 S1PR1 (0.44) FGFR2FGFR1NPC1RAB9APTPRC
SCHEMBL21165796 0.74 L3MBTL1 (0.41) KDM4ENPC1HSD17B10MAPTALDH1A1
SCHEMBL20111217 0.74 L3MBTL1 (0.41) FGFR2FGFR1KDM4ENPC1RAB9A
SCHEMBL20111640 0.73 HTR1A (0.45) KDM4ENPC1RAB9AHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2019-06-18 US disclosed
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180119009-A1 LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE YBX1, PIEZO1, C1S FGFR2 168/4885FGFR1 239/4885KDM4E 1555/4885
US-10323187-B2 Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device YBX1, PIEZO1, C1S FGFR2 168/4885FGFR1 239/4885KDM4E 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.